-
Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity. 2022; 140(supplement):3553-3554.
Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar. View Publication.
-
Poster: ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct 1; 22:s171.
Flowers FC, Burke BJ, Vukcevic VM, Snodgrass SS, Saverno SK, Lumiqued LM, Abdulhaq AH, Brem BE, Evens EA, Farooq FU, Porcu PP, Shadman SM. .
View in:
Publisher Site Mentions:
-
ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct 1; 22:s355-s356.
Flowers FC, Burke BJ, Vukcevic VM, Snodgrass SS, Saverno SK, Lumiqued LM, Abdulhaq AH, Brem BE, Evens EA, Farooq FU, Porcu PP, Shadman SM. .
View in:
Publisher Site Mentions:
-
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin. Leuk Lymphoma. 2022 Dec; 63(12):3008-3011.
Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, Chu R, Andreadis C, Kaplan L, Abdulhaq H, Fakhri B. PMID: 35875857.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957.
Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature. Case Rep Hematol. 2022; 2022:8331766.
Lee M, Martin BA, Abdulhaq H. PMID: 35795542; PMCID: PMC9252825.
View in:
PubMed Mentions:
-
Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. Journal of Clinical Oncology. 2022; 40(16-suppl).
Andrew Hwang, Jason Doornenbal, Daniel Park, Inderpreet Bal, Mohammed SANI Bukari, Yueqi Yan, Haifaa Abdulhaq. . View Publication.
-
Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):8056-8056.
Hwang HA, Doornenbal DJ, Park PD, Bal BI, Bukari BM, Yan YY, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley. Blood. 2021 Nov 5; 138(Supplement 1):4074-4074.
Huang HC, Mahmood MO, Mills MP, Amini AM, Bekal BS, Doornenbal DJ, Bukari BS, Abejie AY, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Blood. 2021 Nov 5; 138(Supplement 1):2509-2509.
Othman OT, Penaloza PJ, Brem BE, Pinter-Brown PL, Baweja BA, Lee LM, Ly LJ, Reid RJ, Abdulhaq AH, Gaut GD, Oliai OC, Reid RE, Tuscano TJ. .
View in:
Publisher Site Mentions:
-
Clinicopathologic Characteristic and Natural History of Patients with Non Hereditary, Non Polycythemia Vera (NH/NPV) Persistent Polycythemia. Blood. 2021 Nov 5; 138(Supplement 1):4617-4617.
Mahmood MO, Mouanoutoua MH, Saini ST, Okura OM, Noori NM, Almasri AN, Abdulhaq AH, Bukari BS. .
View in:
Publisher Site Mentions:
-
OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. Blood. 2021 Nov 5; 138(Supplement 1):2732-2732.
Richardson RP, Schjesvold SF, Abdulhaq AH, Coriu CD, Lazzaro LA, Sonneveld SP, Kullenburg KT, Harmenberg HJ, Thuresson TM, Byrne BC, Mateos MM. .
View in:
Publisher Site Mentions:
-
Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin. Blood. 2021 Nov 5; 138(Supplement 1):2511-2511.
Guan GT, Lo LM, Young YR, Boulbol BF, Mouanoutoua MH, Chu CR, Ai AW, Abdulhaq AH, Fakhri FB. .
View in:
Publisher Site Mentions:
-
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. Cancer Treat Res Commun. 2021; 27:100310.
Barakat M, Albitar M, Whitney R, Abdulhaq H. PMID: 33581493.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review. Case Rep Hematol. 2020; 2020:8823877.
Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, Abdulhaq H. PMID: 33425404; PMCID: PMC7781713.
View in:
PubMed Mentions:
3
-
Using Targeted RNA Next Generation Sequencing and Differential Expression to Compare Primary Central Nervous System Lymphoma with CD+ DLBCL, Nodal DLBCL and EBV+ DLBCL. Blood. 2020 Nov 5; 136(Supplement 1):22-22.
Abdulhaq AH, Albitar AM. .
View in:
Publisher Site Mentions:
-
Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California. 2020; 20:S262-S263.
MatthewLee, TannerMortenson, MahboubNoori, DianaMoers, Mohammed Bukari, HaifaaAbdulhaq. View Publication.
-
ABCL-078: Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California. Clinical Lymphoma Myeloma & Leukemia. 2020 Sep 1; 20:s262-s263.
Lee LM, Mortenson MT, Noori NM, Moers MD, Bukari BM, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
ABCL-407: Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Sirolimus-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: A Case Report. Clinical Lymphoma Myeloma & Leukemia. 2020 Sep 1; 20:s275.
Lee LM, Martin MB, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis. Cureus. 2020 Jul 21; 12(7):e9322.
Hinduja S, Abdulhaq H, Valliani S, Ali MM. PMID: 32850200; PMCID: PMC7444851.
View in:
PubMed Mentions:
-
Clinicopathologic and molecular profile of Philadelphia like ALL in Hispanic population of Central Valley California. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):7524-7524.
Akabane AH, Ali AM, Abdulhaq AH, Bukari BM. .
View in:
Publisher Site Mentions:
-
Clinicopathologic profile of extramedullary plasmacytoma in Central Valley. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e20551-e20551.
Valliani VS, Barakat BM, Gill GH, Okudo OJ, Abdulhaq AH, Bukari BM. .
View in:
Publisher Site Mentions:
-
Leukemic infiltration in the settings of acute respiratory failure. Oxf Med Case Reports. 2019 Nov; 2019(11):482-485.
Fayed M, Evans T, Abdulhaq H. PMID: 31844533; PMCID: PMC6902626.
View in:
PubMed Mentions:
1
-
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):7549-7549.
Barakat BM, Albitar AM, Xu-Monette XZ, Young YK, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):7535-7535.
Barakat BM, Albitar AM, Whitney WR, Chen CC, Kuo KY, Silveira SW, Bukari BM, Arekapudi AS, Dhaliwal-Binning DK, Abdulhaq AH. .
View in:
Publisher Site Mentions:
-
Potential of Germline CDKN2A I49T as a Targetable Driver Mutation: Prolonged Control of Refractory Osteosarcoma with CDK4/6 Inhibitor in a Familial Cancer. Journal of Carcinogenesis & Mutagenesis. 2019 Jan 1; 10(1).
Tehrani TO, Abdulhaq AH, Delozier DC. .
View in:
Publisher Site Mentions:
-
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep Hematol. 2018; 2018:6092646.
Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. PMID: 30225152; PMCID: PMC6129347.
View in:
PubMed Mentions:
17
-
A rare case of rosai-dorfman disease in an adult male associated with auto-immune hemolytic anemia. Mediterr J Hematol Infect Dis. 2013; 5(1):e2013022.
Sachdeva M, Abdulhaq H. PMID: 23667720; PMCID: PMC3647709.
View in:
PubMed Mentions:
5
-
Zosteriform Rash as the First Sign of Metastatic Non-small Cell Carcinoma of the Lung (A Case Report. CHEST Journal. 2011 Oct 1; 140(4):59a-59b.
Tabassomi TM, Abdulhaq AH, Almasri AE, Hashemi HN. .
View in:
Publisher Site Mentions:
-
Viability and potency of hematopoietic progenitor cells after prolonged cryopreservation at -80°C. Acta Haematol. 2011; 126(2):99-102.
Costa R, Khattab M, Gilmore GL, Sahovic EA, Miller SM, Rossetti JM, Abdulhaq H, Lister J. PMID: 21576935.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCells
-
Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011 Jun 15; 117(12):2690-6.
Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J. PMID: 21656746.
View in:
PubMed Mentions:
45 Fields:
Translation:
Humans
-
Viability And Potency Of Hematopoietic Progenitor Cells After Prolonged Cryopreservation At -80 °C. Biology of Blood and Marrow Transplantation. 2010 Feb 1; 16(2):s167.
Khattab KM, Gilmore GG, Sahovic SE, Miller MS, Rossetti RJ, Abdulhaq AH, Lister LJ. .
View in:
Publisher Site Mentions:
-
Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia. Blood. 2009 Nov 20; 114(22):4164-4164.
Benjamin BH, Rossetti RJ, Lampkin LA, Hilton HC, Sahovic SE, Abdulhaq AH, Shadduck SR, Vemulapalli VN, Hercules HA, Lister LJ. .
View in:
Publisher Site Mentions:
-
Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol. 2008 Dec; 31(6):595-605.
Abdulhaq H, Geyer C. PMID: 19060594.
View in:
PubMed Mentions:
7 Fields:
Translation:
Humans
-
Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia. Blood. 2008 Nov 16; 112(11):4041-4041.
Labban LG, Rossetti RJ, Shadduck SR, Sahovic SE, Abdulhaq AH, Goy GJ, Wilt WL, Wonder WR, Lister LJ. .
View in:
Publisher Site Mentions:
-
Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML). Blood. 2008 Nov 16; 112(11):5072-5072.
Abdulhaq AH, Haq HB, Rossetti RJ, Shadduck SR, Sahovic SE, Christianson CD, Lister LJ. .
View in:
Publisher Site Mentions:
-
The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2007 Dec; 16(12):1967-75.
Abdulhaq H, Rossetti JM. PMID: 18042004.
View in:
PubMed Mentions:
9 Fields:
Translation:
HumansAnimals
-
Erythroid variant of chronic myelogenous leukemia. Leukemia. 2008 Apr; 22(4):867-70.
Talreja N, Abdulhaq H, Shadduck RK, Rossetti J, Jalil A, Makary A, Lister J. PMID: 18033324.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Recent advances in myelodysplastic syndromes. Exp Hematol. 2007 Apr; 35(4 Suppl 1):137-43.
Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. PMID: 17379099.
View in:
PubMed Mentions:
6 Fields:
Translation:
HumansCells
-
Response to azacitidine (AZA) in patients with secondary myelodysplastic syndrome. Journal of Clinical Oncology. 2006 Jun 20; 24(18_suppl):6578-6578.
Abdulhaq AH, Haq HB, Rossetti RJ, Lister LJ, Shadduck SR. .
View in:
Publisher Site Mentions: